Caspofungin for the treatment of fungal infections: a systematic review of randomized controlled trials

Sims, 2005, Invasive candidiasis in immunocompromised hospitalized patients, Arch Med Res, 36, 660, 10.1016/j.arcmed.2005.05.015 Pavie, 2005, Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis, J Clin Microbiol, 43, 4902, 10.1128/JCM.43.9.4902-4904.2005 De Miguel, 2005, Nonfatal pulmonary Trichoderma viride infection in an adult patient with acute myeloid leukemia: report of one case and review of the literature, Diagn Microbiol Infect Dis, 53, 33, 10.1016/j.diagmicrobio.2005.04.009 Maschmeyer, 2005, Update on therapy of invasive mycoses in hematology and oncology, Dtsch Med Wochenschr, 130, 1381, 10.1055/s-2005-868738 Forestier, 2005, A case of Aspergillus mediastinitis after heart transplantation successfully treated with liposomal amphotericin B, caspofungin and voriconazole, Eur J Clin Microbiol Infect Dis, 24, 347, 10.1007/s10096-005-1327-5 Ludwig, 2005, Systemic aspergillosis with predominant genitourinary manifestations in an immunocompetent man: what we can learn from a disastrous follow-up, Infection, 33, 90, 10.1007/s15010-005-4070-z Golan, 2005, Overview of transplant mycology, Am J Health Syst Pharm, 62, S17, 10.1093/ajhp/62.suppl_1.S17 Perfect, 2004, Management of invasive mycoses in hematology patients: current approaches, Oncology (Williston Park), 18, 5 Hamza, 2004, Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients, Bone Marrow Transplant, 34, 377, 10.1038/sj.bmt.1704603 Steinbach, 2004, Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients, J Infect, 48, 112, 10.1016/S0163-4453(03)00134-8 Perea, 2002, Invasive Aspergillus infections in hematologic malignancy patients, Semin Respir Infect, 17, 99, 10.1053/srin.2002.33443 Ruhnke, 2002, Management of mycoses in patients with hematologic disease and cancer, review of the literature, Eur J Med Res, 7, 227 Maschmeyer, 2002, New antifungal agents—treatment standards are beginning to grow old, J Antimicrob Chemother, 49, 239, 10.1093/jac/49.2.239 Betts, 2006, Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients, Cancer, 106, 466, 10.1002/cncr.21615 Steinbach, 2005, Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies, Curr Drug Targets Infect Disord, 5, 203, 10.2174/1568005054880145 McCormack, 2005, Caspofungin: a review of its use in the treatment of fungal infections, Drugs, 65, 2049, 10.2165/00003495-200565140-00009 Vazquez, 2005, Anidulafungin: a new echinocandin with a novel profile, Clin Ther, 27, 657, 10.1016/j.clinthera.2005.06.010 Maschmeyer, 2005, Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin, Mycoses, 48, 227, 10.1111/j.1439-0507.2005.01131.x Krcmery, 2005, Antifungal chemotherapeutics, Med Princ Pract, 14, 125, 10.1159/000084627 Perfect, 2004, Antifungal resistance: the clinical front, Oncology (Williston Park), 18, 15 Marr, 2004, Combination antifungal therapy: where are we now, and where are we going?, Oncology (Williston Park), 18, 24 Perfect, 2004, Use of newer antifungal therapies in clinical practice: what do the data tell us?, Oncology (Williston Park), 18, 15 Magiorakos, 2004, Impact of real-time fungal susceptibility on clinical practices, Curr Opin Infect Dis, 17, 511, 10.1097/00001432-200412000-00002 Theuretzbacher, 2004, Pharmacokinetics/pharmacodynamics of echinocandins, Eur J Clin Microbiol Infect Dis, 23, 805, 10.1007/s10096-004-1228-z Gallagher, 2004, Recent advances in antifungal pharmacotherapy for invasive fungal infections, Expert Rev Anti Infect Ther, 2, 253, 10.1586/14787210.2.2.253 Espinel-Ingroff, 2003, In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature, Rev Iberoam Micol, 20, 121 Boucher, 2004, Newer systemic antifungal agents: pharmacokinetics, safety and efficacy, Drugs, 64, 1997, 10.2165/00003495-200464180-00001 Ruhnke, 2004, Mucosal and systemic fungal infections in patients with AIDS: prophylaxis and treatment, Drugs, 64, 1163, 10.2165/00003495-200464110-00002 Rubin, 2004, New options for the treatment of invasive fungal infections, Semin Oncol, 31, 91, 10.1053/j.seminoncol.2004.02.020 Abuhammour, 2004, Newer antifungal agents, Indian J Pediatr, 71, 253, 10.1007/BF02724279 Schwartz, 2003, CNS-aspergillosis: are there new treatment options?, Mycoses, 46, 8 Burnie, 2004, Genetically recombinant antibodies: new therapeutics against candidiasis, Expert Opin Biol Ther, 4, 233, 10.1517/14712598.4.2.233 Wingard, 2004, A new era of antifungal therapy, Biol Blood Marrow Transplant, 10, 73, 10.1016/j.bbmt.2003.09.014 Wong-Beringer, 2003, Systemic antifungal therapy: new options, new challenges, Pharmacotherapy, 23, 1441, 10.1592/phco.23.14.1441.31938 Denning, 2003, Echinocandin antifungal drugs, Lancet, 362, 1142, 10.1016/S0140-6736(03)14472-8 Keating, 2003, Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis, Drugs, 63, 2235, 10.2165/00003495-200363200-00008 Kartsonis, 2003, Caspofungin: the first in a new class of antifungal agents, Drug Resist Updat, 6, 197, 10.1016/S1368-7646(03)00064-5 Wiederhold, 2003, The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy, Expert Opin Investig Drugs, 12, 1313, 10.1517/13543784.12.8.1313 Girmenia, 2003, New antifungal drugs and new clinical trials: interpreting results may be difficult, Curr Opin Oncol, 15, 283, 10.1097/00001622-200307000-00001 Ullmann, 2003, Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole, Curr Med Res Opin, 19, 263, 10.1185/030079903125001884 Sutton, 2002, Laboratory evaluation of new antifungal agents against rare and refractory mycoses, Curr Opin Infect Dis, 15, 575, 10.1097/00001432-200212000-00004 Johnson, 2003, Caspofungin: first approved agent in a new class of antifungals, Expert Opin Pharmacother, 4, 807, 10.1517/14656566.4.5.807 Vazquez, 2003, Invasive oesophageal candidiasis: current and developing treatment options, Drugs, 63, 971, 10.2165/00003495-200363100-00004 Cornely, 2002, The first echinocandin: caspofungin, Mycoses, 45, 56, 10.1111/j.1439-0507.2002.tb04771.x Letscher-Bru, 2003, Caspofungin: the first representative of a new antifungal class, J Antimicrob Chemother, 51, 513, 10.1093/jac/dkg117 Polak A. Antifungal therapy—state of the art at the beginning of the 21st century. Prog Drug Res 2003;Spec No:59–190. Chandrasekar, 2002, Caspofungin, Drugs Today (Barc), 38, 829, 10.1358/dot.2002.38.12.820101 Pacetti, 2003, Caspofungin acetate for treatment of invasive fungal infections, Ann Pharmacother, 37, 90, 10.1345/aph.1C114 Sable, 2002, Safety and tolerability of caspofungin acetate in the treatment of fungal infections, Transpl Infect Dis, 4, 25, 10.1034/j.1399-3062.2002.01004.x Arathoon, 2001, Clinical efficacy of echinocandin antifungals, Curr Opin Infect Dis, 14, 685, 10.1097/00001432-200112000-00004 Stone, 2002, Caspofungin: an echinocandin antifungal agent, Clin Ther, 24, 351, 10.1016/S0149-2918(02)85039-1 Groll, 2001, Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections, Expert Opin Investig Drugs, 10, 1545, 10.1517/13543784.10.8.1545 Graybill, 2001, Hitting a new target with echinocandins. Why chase something else?, Curr Opin Investig Drugs, 2, 468 Hoang, 2001, Caspofungin acetate: an antifungal agent, Am J Health Syst Pharm, 58, 1206, 10.1093/ajhp/58.13.1206 Georgopapadakou, 2001, Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors, Expert Opin Investig Drugs, 10, 269, 10.1517/13543784.10.2.269 DiNubile, 2005, Invasive candidiasis in cancer patients: observations from a randomized clinical trial, J Infect, 50, 443, 10.1016/j.jinf.2005.01.016 Stone, 2004, Potential for interactions between caspofungin and nelfinavir or rifampin, Antimicrob Agents Chemother, 48, 4306, 10.1128/AAC.48.11.4306-4314.2004 Walsh, 2004, Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia, N Engl J Med, 351, 1391, 10.1056/NEJMoa040446 Colombo, 2003, Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis, Eur J Clin Microbiol Infect Dis, 22, 470, 10.1007/s10096-003-0973-8 Arathoon, 2002, Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases, Antimicrob Agents Chemother, 46, 451, 10.1128/AAC.46.2.451-457.2002 Mora-Duarte, 2002, Caspofungin invasive candidiasis study group. Comparison of caspofungin and amphotericin B for invasive candidiasis, N Engl J Med, 347, 2020, 10.1056/NEJMoa021585 Villanueva, 2002, A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis, Am J Med, 113, 294, 10.1016/S0002-9343(02)01191-9 Dinubile, 2002, Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin, AIDS Res Hum Retroviruses, 18, 903, 10.1089/088922202760265579 Stone, 2002, Single- and multiple-dose pharmacokinetics of caspofungin in healthy men, Antimicrob Agents Chemother, 46, 739, 10.1128/AAC.46.3.739-745.2002 Villanueva, 2001, A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis, Clin Infect Dis, 33, 1529, 10.1086/323401 Jadad, 1996, Assessing the quality of reports of randomized clinical trials: is blinding necessary?, Control Clin Trials, 17, 1, 10.1016/0197-2456(95)00134-4 Betts, 2006, Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients, Cancer, 106, 466, 10.1002/cncr.21615 Abruzzo, 2000, Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice, Antimicrob Agents Chemother, 44, 2310, 10.1128/AAC.44.9.2310-2318.2000 Abruzzo, 1997, Evaluation of the echinocandin antifungal MK-0991 (L-743, 872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis, Antimicrob Agents Chemother, 41, 2333, 10.1128/AAC.41.11.2333 MacCallum, 2004, Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection, Antimicrob Agents Chemother, 48, 4911, 10.1128/AAC.48.12.4911-4914.2004 Ramage, 2002, In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time–kill studies, Antimicrob Agents Chemother, 46, 3634, 10.1128/AAC.46.11.3634-3636.2002 Ostrosky-Zeichner, 2003, Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States, Antimicrob Agents Chemother, 47, 3149, 10.1128/AAC.47.10.3149-3154.2003 Zaoutis, 2005, Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals, Diagn Microbiol Infect Dis, 52, 295, 10.1016/j.diagmicrobio.2005.03.002 Cuerca-Estella, 2005, In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002–2003, J Antimicrob Chemother, 55, 194, 10.1093/jac/dkh548 Arikan, 2005, In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital, Med Mycol, 43, 171, 10.1080/13693780410001731565 Ju, 2002, Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox−/− knockout mice, Antimicrob Agents Chemother, 46, 1240, 10.1128/AAC.46.5.1240-1245.2002 Barchiesi, 2005, Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata, Antimicrob Agents Chemother, 49, 4989, 10.1128/AAC.49.12.4989-4992.2005 Wegner, 2005, Caspofungin is less nephrotoxic than amphotericin B in vitro and predominantly damages distal renal tubular cells, Nephrol Dial Transplant, 20, 2071, 10.1093/ndt/gfh948 Keating, 2003, Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis, Drugs, 63, 2235, 10.2165/00003495-200363200-00008